ZFA-Logo

Should I Change my Anticoagulated Patients to Dabigatran?

DOI: 10.3238/zfa.2012.0043-0046

german translation / full article

Günther Egidi

Keywords: Atrial fibrillation Phenprocoumon Anticoagulation Dabigatran

Summary: In August 2011 the European Drug Agency (EMA) has licensed dabigatran for patients with atrial fibrillation. We summarize arguments from the family medicine listserver in a pro and con format. Should I change my anticoagulated patients on warfarin/phenprocoumon to dabigatran? Pro: Prescribing dabigatran offers slight advantages and has the potential to minimize costs. Dabigatran represents a true innovation and handling the drug seems to be more comfortable for family practices. In the end sick funds must decide whether they are prepared to pay for this comfort of their members. Con: Scientific data argue against an uncontrolled application of dabigatran. Flaws of the RE-LY study and important disadvantages when using the drug in daily practice are the most important reasons to adhere to anticoagulation as used until today. Available ressources should rather be used for better INR-monitoring.


(State: 15.03.2012)

Latest Issue 2/2021

In Focus

  • How Much Economy is Tolerated by „Good“ Medicine?
  • Adult Attention-Deficit Hyperactivity Disorder (ADHD)
  • Medical Education in France